Perampanel 3/4 hydrate is a selective, non-competitive AMPA receptor antagonist used as an active pharmaceutical ingredient (API) in the development and manufacturing of antiepileptic medications. It is primarily indicated for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy aged 12 years and older. By blocking AMPA receptors, it reduces excessive neuronal excitation in the brain, thereby decreasing seizure frequency and severity. This compound is typically formulated into oral tablets for clinical use and is often employed as adjunctive therapy when other antiepileptic drugs are inadequate. As a specialty chemical, it is supplied as a high-purity powder for pharmaceutical research, synthesis, and production. Potential side effects in therapeutic use include dizziness, somnolence, and mood alterations; ongoing research explores its applications in other neurological disorders.